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ABSTRACT
Fecal microbiota transplant (FMT) has emerged
as a highly efficacious treatment for difficult
cases of refractory and/or recurrent Clostridium
difficile infection (CDI). There have been many
well-conducted randomized controlled trials
and thousands of patients reported in case series
that describe success rates of approximately
90% following one or more FMT. Although the
exact mechanisms of FMT have yet to be fully
elucidated, replacement or restoration of a
‘normal’ microbiota (or at least a microbiota
resembling those who have never had CDI)
appears to have a positive effect on the gut
dysbiosis that is thought to exist in these
patients. Furthermore, despite being aestheti-
cally unappealing, this ‘ultimate probiotic’ is a
particularly attractive solution to a difficult
problem that avoids repeated courses of antibi-
otics. The lack of clarity about the exact mech-
anism of action and the ‘active ingredient’ of
FMT (e.g., individual or communities of bacte-
ria, bacteriophage, or bioactive molecules such
as bile acids) has hindered the ability to produce
a standardized and well-characterized FMT
product. There is no standard method to pro-
duce material for FMT, and there are a multi-
tude of factors that can vary between
institutions that offer this therapy. Only a few
studies have directly compared clinical efficacy
in groups of patients who have been treated
with FMT prepared differently (e.g., fresh vs.
frozen) or administered by different route (e.g.,
by nasojejunal tube, colonoscopy or by oral
administration of encapsulated product). More
of these studies should be undertaken to clarify
the superiority or otherwise of these variables.
This review describes the methods and proto-
cols that two English NHS hospitals indepen-
dently adopted over the same time period to
provide FMT for patients with recurrent CDI.
There are several fundamental differences in the
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methods used, including selection and testing
of donors, procedures for preparation and stor-
age of material, and route of administration.
These methods are described in detail in this
review highlighting differing practice. Despite
these significant methodological variations,
clinical outcomes in terms of cure rate appear to
be remarkably similar for both FMT providers.
Although both hospitals have treated only
modest numbers of patients, these findings
suggest that many of the described differences
may not be critical factors in influencing the
success of the procedure. As FMT is increasingly
being proposed for a number of conditions
other than CDI, harmonization of methods and
techniques may be more critical to the success
of FMT, and thus it will be important to stan-
dardize these as far as practically possible.
Keywords: Clostridium difficile; Dysbiosis; Fecal
microbiota transplantation; Gut microbiome;
Microbiota replacement therapies; Stool bank
INTRODUCTION
Since the publication of a number of random-
ized controlled trials demonstrating its efficacy
in treating recurrent Clostridium difficile Infec-
tion (rCDI) [1–8], and subsequent National
Institute for Health and Care Excellence (NICE)
Interventional Procedure Guideline IPG485 [9],
fecal microbiota transplantation (FMT) has
increasingly been adopted by some healthcare
centers as a valuable management option in this
difficult-to-treat patient group. A national sur-
vey conducted in 130 sites in the UK in 2015
found that 36 (28%) of centers had performed at
least one FMT [10].
Up to 25% of patients treated with metron-
idazole or vancomycin will suffer a recurrence
within 30 days [11–13], and approximately
45–65% of these will have a second recurrence
[14, 15]. Rates of recurrence have recently
increased, potentially related to the spread of
the epidemic BI/NAP1 027 strain [16]. The
introduction of newer therapies such as fidax-
omicin [11, 12, 17–19] and bezlotoxumab
[20, 21] have been shown to significantly reduce
the risk of recurrence; however, there are a
number of patients whose microbiome is
seemingly disrupted to such an extent that the
most effective management is the restoration of
a healthier microbiota through FMT [22].
Prior randomized controlled studies demon-
strated the efficacy and short-term safety of FMT
[1–8], with a corresponding increase in pub-
lished studies and interest amongst both clini-
cians and patients [23].
A number of national and international
guidelines now include FMT as a treatment
option (usually following a second or further
recurrence) after failure with standard anti-C.
difficile antibiotics [9, 24–28]. In addition, there
are at least two sets of consensus recommen-
dations based on literature review and agree-
ment using Delphi methodology by experts in
the field [29, 30].
Despite this, there are limited data compar-
ing practice across a range of factors, such as
donor selection and testing, preparation and
storage of material, and route of administration
of FMT. Consequently, in clinical practice, FMT
methods and protocols are unstandardized,
with individual centers developing their own
local policies and procedures based on their
own experience.
We aimed to describe the practical use of
FMT to treat patients with rCDI at two NHS
hospitals in England. Both hospitals indepen-
dently chose to undertake FMT using signifi-
cantly different methods and procedures. We
examine the key differences in these two pro-
viders and compare outcomes in terms of clin-
ical success and adverse events.
Compliance with Ethics Guidelines
This article is based on previously conducted
studies and does not contain any studies with
human participants or animals performed by
any of the authors.
Setting
FMT was adopted for use in patients with rCDI
at two English National Health Service (NHS)
hospitals: Guy’s and St Thomas’ NHS
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Foundation Trust in London, and Norfolk and
Norwich University Hospitals NHS Founda-
tion Trust. Both hospitals introduced FMT in
2014.
Guy’s and St. Thomas’ Hospitals (provider A)
is a secondary and tertiary academic center with
1100 beds providing 2.4 million patient con-
tacts (daycase, inpatient and outpatient) per
year. Norfolk and Norwich University Hospitals
(provider B) is a 1000-bed acute secondary and
tertiary care hospital providing 1 million
patient contacts per year. Both providers have
comprehensive microbiology, infection control,
and gastroenterology services.
Indications and Exclusions for FMT
Indications for FMT in provider A are rCDI (at
least three distinct episodes) that have been
treated with standard anti-C. difficile antibiotics,
including either fidaxomicin or pulsed/tapered
vancomycin. A second indication is in severe or
fulminant CDI as an adjunct to either fidax-
omicin or vancomycin that has failed to achieve
sufficient clinical response after 5 days of
therapy.
Indications in provider B are rCDI (three
episodes or more as judged by a multi-disci-
plinary team comprising a microbiologist and
gastroenterologist) with no requirement for
specific antibiotic treatment. FMT is also offered
to selected patients after the first recurrence
(second episode) if there are other complicating
co-morbidities (e.g., diabetes mellitus, chronic
renal failure, etc.), justified indications for on-
going or recurrent concomitant antibiotics, or
severe disease.
There are three main contraindications to
FMT at provider A, which are all relative. (1)
Major immunosuppressive state [(high-dose
steroids equivalent to [60 mg pred-
nisolone/day, mechanistic target of rapamycin
(mTOR) inhibitors, lymphocyte-depleting
agents, anti-TNF agents, other chemotherapeu-
tic antineoplastic agents within the last 6 weeks,
advanced HIV/AIDS with CD4 \240, bone
marrow transplant, solid organ transplant
recipient); (2) decompensated liver disease; and
(3) life-threatening food allergies, e.g., nuts, etc.
Provider A does not have any age exclusions
and treats children.
Provider B has only one absolute exclusion
criterion which is children under the age of
16 years. Relative exclusions include severe
colitis warranting intensive care admission,
toxic megacolon and concurrent non-C. difficile
broad-spectrum antibiotics.
Donor Selection and Screening
Both providers use mainly unrelated donors
who are anonymous to the recipient. Both
providers have accommodated requests to per-
form donor-directed procedures (using either
related household members or friends of the
recipient); however, for logistical reasons,
anonymous donors are preferred.
Provider A uses a mixture of hospital
employees (and partners/friends of hospital
employees) who are almost exclusively non-
clinical, together with a number of donors from
the general public (who are healthy but have
been previous patients at the hospital).
Provider B excludes clinical staff from being
donors and uses mainly research staff and sci-
entists (non-clinical, research staff) as donors.
Neither provider financially compensates
donors for their time. This approach was adop-
ted in line with standard practice for blood
donation and is in accordance with the World
Health Organizations Melbourne Declaration
on voluntary, non-remunerated donation [31].
Provider A uses a detailed questionnaire as a
screening tool which is completed in conjunc-
tion with a microbiologist or infectious diseases
physician assessment. Table 1 lists factors which
would preclude donation. If the material is to be
used in those born after 1997, a donor who did
not live in the UK prior to 1996 is used to
minimize the risk of transmission of CJD/vCJD.
Provider B uses a previously published donor
screening questionnaire administered by the
recruiting microbiologist after extensive dis-
cussions with the potential donor [32]. This is
very similar to that used by provider A, but does
not have any restrictions regarding age, body
mass index or receipt of oral medications. The
potential donor is given written information
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about the donor screening process, screening
frequency and consent forms to take away to
read, and another appointment is made to
proceed when they are ready and all questions
have been satisfactorily answered.
Donor Testing
Provider A tests donors who do not fall into any
of the aforementioned exclusion criteria using
serology and stool testing. Serology tests
include HIV 1?2 antigen/antibodies, HTLV I/II
antibodies, hepatitis A IgM, hepatitis B surface
antigen and core antibody, hepatitis E IgG and
IgM, Treponema palladium antibodies, Cytome-
galovirus IgM, Epstein Barr Virus IgG and IgM,
Strongyloides ELISA. Provider B performs the
same tests but also includes serology for Heli-
cobacter pylori and Entamoeba histolytica.
Provider A tests stool samples for the fol-
lowing: multiplex PCR for Campylobacter, Sal-
monella, Shigella and Verocytotoxin producing
E. coli; concentration and microscopy for ova,
cysts and parasites, GDH, toxin A/B EIA and
PCR for Clostridium difficile, norovirus PCR,
antigen for Helicobacter pylori, Entamoeba his-
tolytica PCR, resistant Gram-negative organism
culture, methicillin-resistant Staphylococcus aur-
eus (MRSA) culture. Provider A has used a total
of 8 different donors to date and has excluded
10 on the basis of risk factors or positive test
results.
Provider B tests stool for Campylobacter, Sal-
monella, Shigella and E. coli O:157 using culture.
Tests for C. difficile include GDH and toxin A/B
EIA. Provider B screens for multi-drug-resistant
pathogens including MRSA, extended spectrum
beta-lactamase-producing organisms (ESBLs),
Table 1 Criteria for selecting an FMT donor
Factors which preclude donation include
Age under 18 or over 60
Body mass index over 25
Currently taking any prescribed oral medications
Known to be infected with HIV/HTLV/Hepatitis A/B/C/E; active EBV or CMV
Active diarrhea (deﬁned as three or more unformed bowel movements for at least 2 consecutive days)
High-risk sexual behavior, including sexual intercourse with those known to have HIV or hepatitis, sexual intercourse with
commercial sex workers, and men who have sex with men, unless they have abstained from sex for the past 3 months
Use of recreational drugs
Tattoos or body piercings within the last 6 months
History of being in prison anytime in the last 12 months
Inﬂammatory bowel disease, irritable bowel syndrome, gastrointestinal malignancy or polyps, any other gastrointestinal
disorder, previous gastrointestinal surgery
Metabolic syndrome, diabetes, any systemic autoimmune disease, e.g., multiple sclerosis, connective tissue disorder
Use of systemic antibiotics within the past 3 months
Colonization with antibiotic-resistant bacteria (MRSA/VRE/CRO)
Major immunosuppressive agents
Atopy including eczema and asthma
Chronic pain syndromes, e.g., chronic fatigue, ﬁbromyalgia
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carbapenemase-producing enterobacteriaceae
(CPE) and vancomycin-resistant enterococci
(VRE). All other stool testing is the same as
described for provider A. To date, 6 donors have
expressed interest of which 4 have been
screened and 3 of these have donated. There has
been one occasion where a donor could not
donate due to recent upper respiratory tract
infection and another where the donor had
recent antibiotics. So far, all 4 donors who have
undergone microbiological testing have passed.
In addition to initial donor testing, all
accepted donations at provider A are further
tested for Campylobacter, Salmonella, Shigella,
verocytotoxin producing E. coli, norovirus, C.
difficile and parasites, using the methods
described above. All serological testing and
resistant bacteria stool testing are repeated at
3-monthly intervals. Provider B recalls donors
for repeat microbiological tests every 6 months.
Both providers use a secondary question-
naire for each occasion the volunteer donates.
This asks about symptoms and risk factors
which have emerged between the date of initial
questionnaire completion and time of dona-
tion. This includes diarrhea and vomiting,
fever, jaundice, lymphadenopathy, sore throat,
use of antibiotics, travel outside the UK, intra-
venous drug use and new sexual partners. If the
donor reports any of these symptoms or risk
factors, he/she may be excluded from donating
(either permanently or for a minimum of
3 weeks before undergoing a full set of labora-
tory tests as described above).
Preparation of Material for FMT
Material is processed within 6 h of donor pro-
duction (however, this is nearly always achieved
within 2 h) at provider A. Material is processed
in a class II biosafety cabinet using ambient air.
Between 50 and 100 g of stool is mixed with
approximately 150 mL of sterile 0.9% sodium
chloride. This is mixed using a food grade dis-
posable mixer of the type used to prepare pro-
tein drinks. Once homogenized, the mixture is
poured through a disposable kitchen-grade
nylon sieve to remove large particles. Further
0.9% saline and 12.5% glycerol (as a
cryopreservant) are added to achieve a final
volume of 250 mL for colonoscopic adminis-
tration (or 150 mL if using the nasojejunal
route).
Provider B uses approximately 80 g of stool
which is added to a stomacher bag with 400 mL
sterile 0.9% sodium chloride. This is homoge-
nized for 1 min in the stomacher at 230 rpm.
The resulting slurry is filtered, decanted and
stored in seven 60-mL capped oral syringes (fi-
nal volume of 420 mL) for nasojejunal admin-
istration within 4 h of production.
Storage of FMT Material
At provider A, material for FMT is labeled and
stored frozen at - 80 C until required. Banked
material is stored for a maximum of 6 months
before being discarded as clinical waste. Re-
freezing once defrosted is not permitted. There
are several in vitro and clinical studies sup-
porting the stability of material for FMT when
stored in these conditions [3, 6, 8, 33–35]. Pro-
vider B uses freshly prepared material which is
used within 4 h of preparation or otherwise
discarded as clinical waste. Both providers
archive aliquots of donation material indefi-
nitely at - 80 C in the event that these need
further testing, e.g., in the case of an adverse
event or as part of a look-back investigation.
Identification of Recipients and Method
of FMT Administration
Referrals (internal or external) at provider A are
made either to the microbiology or gastroen-
terology department who assess the patient for
eligibility. The service is provided jointly by the
departments of microbiology and gastroen-
terology either on an inpatient or outpatient
basis. Provider A primarily administers FMT by
colonoscope, but has occasionally administered
using a nasojejunal tube. The procedure is
undertaken in the endoscopy suite at the end of
a routine list to allow enhanced environmental
cleaning following the procedure.
Provider B identifies potential patients using
laboratory data and during weekly multi-
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disciplinary C. diffiicile ward rounds. The pri-
mary route of delivery for hospital B is via
nasojejunal tube and occasionally via sigmoi-
doscopy when a nasojejunal tube cannot be
tolerated. This is performed at the patient bed-
side in an isolation room with bathroom facili-
ties or in the endoscopy suite if carried out as an
outpatient or via a sigmoidoscopy route.
There are a number of studies that have used
various methods of administration which
include an upper gastrointestinal route (via
nasogastric, nasojejunal or nasoduodenal tube),
lower gastrointestinal (via retention enema or
colonoscopy) or using capsules (either fresh
frozen or lyophilized). One randomized study
comparing upper and lower GI administration
found a non-significantly higher cure rate with
colonoscopy; however, this was a pilot study
with only five and six patients in each arm [8].
Another randomized controlled trial com-
paring capsules with FMT by colonoscopy
reported no difference in overall cure rates [4].
However, other studies including four meta-
analyses have suggested that colonoscopic
administration has better cure rates than the
upper GI route [36–39]. Additionally, a large
case series of 2050 patients has demonstrated
that FMT by colonoscopy (85.8% clinical cure,
n = 1441) was superior to upper endoscopy
(74.1% clinical cure, n = 201) (P\0.01) [40].
Recipient Preparation
Provider A administers a minimum of 5 days’
pre-treatment with either vancomycin 125 mg
four times/day (unless on a tapering course) or
fidaxomicin 200 mg twice daily. This is discon-
tinued 2 days prior to the procedure.
Bowel preparation is given as per normal
protocol for diagnostic colonoscopy using
macrogol (Moviprep) along with standard pre-
colonoscopy dietary recommendations of no
solid foods for 24 h. Then, 8 mg of loperamide is
administered orally pre-procedure to aid reten-
tion of transplant material. For colonoscopi-
cally administered FMT, conscious sedation
with fentanyl and midazolam is administered as
per routine colonoscopy. On insertion of the
colonoscope, an effort is made to use minimal
air insufflation and suction of fluid pools is
performed. The FMT material is drawn up into
multiple 50-ml ‘slip tip’ syringes and pushed
rapidly down the biopsy channel of the
colonoscope into the cecum (or administered as
proximally as possible if unable to reach the
cecum), followed by 20 ml of saline.
For nasojejunal delivery, a proton pump
inhibitor (e.g., omeprazole 20 mg twice daily) is
administered for 2 days prior to the FMT. On
the day of the FMT, a nasojejunal tube with a
minimum gauge of 9 Fr (as smaller diameter
tubes tend to block and require force to instill
due to the viscosity of the material) is inserted
in endoscopy. The patient is then turned onto
their back and sat up on the trolley. The FMT is
drawn into 20-ml Luer lock feeding syringes and
instilled slowly at 10 ml/min. The patient is
carefully observed for signs of coughing or
vomiting and, if detected, the infusion aborted.
Provider B recommends a minimum of
4 days of vancomycin 500 mg four times per
day (stopping the evening before the procedure)
prior to the FMT. Provider B initially used bowel
prep with a macrogol-containing solution the
day before the procedure as per the manufac-
turer’s instructions or until bowel motions
become watery and clear. Subsequently, bowel
lavage was discontinued due to lack of strong
evidence of effectiveness [40]. Patients are fasted
overnight but permitted to take sips of water or
fruit juice up to 1 h prior to the procedure. No
gastric acid-suppressing agent is used.
Both providers offer an information leaflet
which is given to the patient, and they are
consented for the procedure as per usual clinical
practice.
Immediate Recovery and Monitoring
Immediate recovery and monitoring are the
same as for a diagnostic colonoscopy at provider
A. For colonoscopic administration, patients are
warned that they are likely to experience some
diarrhea immediately following the procedure.
The patient may be discharged once sufficiently
recovered later the same day and can eat and
drink on discharge. For nasojejunal adminis-
tration, the tube is removed immediately after
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administration. The patient is advised to main-
tain an upright position for a minimum of 2 h
after which time they can eat and drink as
normal.
Provider B monitors for a short time period
(until first bowel movement) and allows fluids
1 h after the procedure. The nasojejunal tube
is removed 30–60 min after the procedure
[41].
Patient Follow Up and Criteria for Success
Patients at provider A are offered a gastroen-
terology outpatient clinic appointment after
2 months. If the patient declines or fails to
attend (or if they do not live in the local area), a
follow-up appointment is undertaken by tele-
phone. Clinical cure is defined as resolution of
diarrhea with no further requirement for anti-C.
difficile treatment at 8 weeks or more following
FMT. Stool samples are not routinely taken for
C. difficile testing providing clinical cure is
achieved. Recurrence is defined as return or
ongoing diarrhea with positive stool test for C.
difficile (GDH antigen plus toxin A/B EIA and
PCR for toxin gene).
Hospital B follows patients up for as long as
they remain an inpatient, and encourages
patients to contact their clinical team in the
event of a possible recurrence.
Governance Arrangements, Reporting
and Investigation of Adverse Events
Both providers have a clinical guideline which
sets out criteria for FMT and any contraindica-
tions. This is approved by the hospital Clinical
Governance Committee and Drugs and Thera-
peutic Committee. In addition, a Standard
Operating Procedure is used to ensure consis-
tency in processing, storage and preparation of
material. Although FMT in the UK is not regu-
lated by the Human Tissue Authority, the
standards outlined in the Human Tissue Act
2004, the Human Tissue (Quality and Safety for
Human Application) Regulations 2007 [42] and
the HTA’s Codes of Practice [43] are followed as
far as is practically possible. In particular, there
are procedures to ensure that donor and
recipient documentation is collected and
maintained to ensure traceability.
Outcomes
To date (September 2017), a total of 36 patients
have been treated by provider A. Patients had a
mean age of 75 years with a range of 4–92. Two
children aged 4 and 15 have also been treated.
Three patients had FMT via nasojejunal tube,
one via a loop ilesotomy and the remainder by
colonoscopy. Two patients had a laboratory-
confirmed recurrence (both after at least
4 months of being symptom-free, and both after
taking further courses of antibiotics). We did
not observe any short-term adverse events
directly related to the FMT; however, there were
two patient deaths within 3 months of FMT,
neither of which were determined to be directly
related to FMT.
Hospital B has conducted 27 procedures in
26 patients with a mean age of 72 years (range
41–91). One patient has received FMT twice due
to a further relapse after 3 months. A total of 24
procedures were via nasojejunal tube and 2 via
sigmoidoscopy. The majority of patients did not
have any significant adverse events. However,
one 81-year-old patient had an episode of
vomiting immediately following nasojejunal
administration of FMT. The patient subse-
quently developed an aspiration pneumonia
and died 10 days later. This was thought to be as
a result of the FMT procedure at provider B, and
a similar case has been previously reported [44].
There is a general lack of long-term safety
data in the literature, with most studies fol-
lowing patients for a mean of between 3 and
24 months [45]. One systematic review of 18
observational studies involving 611 patients
reported 38 deaths, 6 of which were associated
with relapsed or severe CDI and 3 with other
infectious diseases such as pneumonia and
peritonitis [45]. A larger review including 109
publications and 1555 patients reported 3
deaths potentially attributable to FMT [46].
Other commonly reported adverse events
include diarrhea, bloating, flatulence and
abdominal pain/cramping, which are almost
always mild–moderate and self-limiting [45–47].
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DISCUSSION
There were several significant differences in the
methods and procedures used in administering
FMT to patients with rCDI in these two
healthcare providers, which are summarised in
Table 2. This is perhaps not surprising since
there are very few data demonstrating superi-
ority of any one method or protocol. Centers
have adopted different practices according to
evidence available at the time, iteratively
adapting their protocols when the need arises.
In the absence of well-conducted studies to
determine optimal methods and procedures,
centers are likely to continue using approaches
that are already in place or are convenient to
the patient and/or clinician.
There are a number of European consensus
documents which attempt to address key issues;
however, a significant proportion of recom-
mendations are based only on expert opinion
[26, 29, 30]. For example, of the 28 statements
in the European consensus document, 19 (68%)
have only weak supporting evidence, 5 (18%)
moderate supporting evidence and only 4 (14%)
have strong evidence [29]. This lack of clear
evidence-based guidelines has been suggested as
a barrier to the more widespread adoption of
FMT as a treatment modality in the UK and
other countries [48–50].
One of the most fundamental sources of
variation is the route of FMT administration.
One systematic review which compared various
routes of administration included a total of 182
patients (148 received FMT via colonoscopy and
34 received FMT via nasogastric tube) from 12
published studies [51]. Recurrence of CDI after
FMT was similar in both the colonoscopy group
(8/148, 5.4%) versus the NGT group (2/34,
5.9%) (P = 1.000). However, the overall rate of
cure after FMT was slightly higher in patients
receiving FMT by colonoscopy: 85.3% (29
patients, 29/34) in the nasogastric tube group
and 93.2% (138 patients, 138/148) in the colo-
noscopy group (P = 0.162). A larger and more
recent systematic review of 14 studies including
305 patients comparing FMT delivery by upper
and lower gastrointestinal routes also favored
lower gastrointestinal delivery [52]. At 30 and
90 days, the risk of clinical failure was 5.6 and
17.9% in the upper gastrointestinal group
compared with 4.9 and 8.5% in the LGI delivery
route group, respectively. Expert consensus
opinion does not provide a preference for the
route of administration in terms of efficacy, but
notes that lower gastrointestinal administration
may be associated with fewer adverse events
[30]. More recently, encapsulated preparations
of FMT have been used with success [4, 53–57].
This route has the advantage of being less
invasive and simpler, which may also result in
improved cost-effectiveness. However, colono-
scopic administration also allows for identifi-
cation of alternative diagnoses.
The source and screening of donors, the
amount of stool used and the processing of FMT
preparations, storage and use of product (fresh
or frozen), and several other factors have all
being described in varying ways in the current
literature. However, there is a lack of evidence
to suggest superiority of many of these
variables.
The period of time following discontinua-
tion of anti-C. difficile antibiotics and FMT
procedure would seem to be a critical variable to
ensure that transplanted material is not delete-
riously damaged by any residual antibiotic in
the gastrointestinal tract. Studies report a wash-
out period ranging from 1 to 3 days
[4, 6, 7, 47, 58–70].
One study has demonstrated that van-
comycin remains detectable in feces for 4–-
5 days after discontinuation of therapy [71],
which could potentially and significantly
impact the success of the procedure. However,
the cited report did not study patients who had
been given bowel preparation, which presum-
ably would reduce the remaining concentration
of antibiotic, so limiting its effect on the FMT
material.
Based on our clinical experience so far, this
heterogeneity does not appear to materially
affect clinical outcomes. Remarkably, nearly all
patients who have received FMT in our centers
have responded favorably (100% success rate at
4 months and 94% overall success rate for pro-
vider A and 96% after one treatment for provi-
der B). This suggests that these variables have
limited or no influence on clinical outcomes.
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Table 2 Main differences in practice at each provider
Provider A Provider B
Indications Three episodes of CDI treated with either ﬁdaxomicin
or prolonged/tapered vancomycin
Three episodes of CDI with no requirement
for speciﬁc anti-C. difﬁcile antibiotics
Severe/fulminant CDI as an adjunct to anti-C. difﬁcile
antibiotics
Absolute
contraindications
Provider A treats all ages Children under 16 years
Relative
contraindications
Major immunosuppressive states Severe colitis requiring ICU admission
Decompensated liver disease Toxic megacolon
Life-threatening food allergy Concurrent non-anti-C. difﬁcile antibiotics
Donor selection Allows hospital employees to be donors Excludes clinical staff from donating
Excludes those under 18 and over 60 years of age No age range speciﬁed
Excludes those with body mass Index over 25 No body mass index exclusions
Excludes those taking and oral medications No oral medication exclusions
Donor testing Uses stool antigen for Helicobacter pylori Uses serology for Helicobacter pylori
Uses PCR for detection of Campylobacter, Salmonella,
Shigella and verocytotoxin producing E. coli
Uses culture for these pathogens
Does not test for ESBLs or VRE Tests for ESBLs and VRE
Preparation of
FMT material
Uses 50–100 g stool in 250 mL 0.9% sodium choride
with 12.5% glycerol
Uses 80 g stool in 420 mL 0.9% sodium
chloride
Uses manual mixing with a disposable protein shaker
bottle
Uses an automated stomacher bag
Storage of FMT
material
Stored at - 80C for up to 6 months Uses fresh material only within 4 h of
production
Method of
administration
Primarily by colonoscopy in the endoscopy suite Using nasojejunal tube at the patient
bedside
Recipient
preparation
Administers 5 days of anti-C. difﬁcile antibiotic with a
48-h ﬂush-out period prior to FMT
Administers 4 days of anti-C. difﬁcile
antibiotic with a 24-h ﬂush-out period
prior to FMT
Bowel preparation with macrogol Bowel preparation not given
Loperamide administered to aid retention of FMT
Patient
demographics
36 patients treated with mean age of 75 years (range
4–92 years)
26 patients treated with mean age of
72 years (range 41–91 years)
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The mechanism by which FMT exerts its
effect is not fully elucidated. A number of
‘modes of action’ have been proposed, includ-
ing direct competition with indigenous gut
microbiota, actions of secondary bile acids and
immune-mediated colonization resistance [72].
Of note, a recent study which used sterile fecal
filtrate to treat CDI suggests that the microor-
ganisms within the FMT material may not be
exerting any significant beneficial effect [73].
This supports the notion of other bioactive
compounds in stool (e.g., various bile acids and
other metabolites) as a potential mechanism of
action [74, 75]. Others suggest bacteriophages
may play a significant role [76–78].
Further complicating matters in the UK set-
ting is the classification of material prepared for
FMT as a medicinal product by the Medicine
and Healthcare Products Regulatory Agency
(MHRA). This places a number of additional
requirements on manufacturers and providers
of FMT. In particular, any clinical research using
FMT is likely to be classed as a Clinical Trial of
an Investigational Medicinal Product and, as
such, material would need to be produced
according to the principles of Good Manufac-
turing Practice under MHRA licence. This is a
significant commitment in terms of infrastruc-
ture and oversight and could be a significant
barrier to the advancement of clinical research
using FMT in the UK [79–82].
Ultimately, development of a defined mix-
ture of cultured bacteria may be safer and more
acceptable to patients and clinicians and allows
standardization and control [83–86]. Such
standardization would also allow rational
design of clinical trials [87]. If such a product
was produced commercially and was licensed,
this could potentially facilitate more wide-
spread adoption of FMT by healthcare provi-
ders, but is likely to take many years. In the
interim, the formation of a national or regional
stool banks, similar to that established in the
Netherlands and other countries, could help to
overcome the difficulty of access to donor
material [88].
The effectiveness with which FMT has been
used to treat rCDI provides hope that this
therapy might also be useful in an increasing
number of diseases which have been linked to a
disturbed intestinal microbiota composition,
including obesity and metabolic syndrome
[89–91], irritable bowel syndrome, inflamma-
tory bowel diseases [92–95] hepatic
encephalopathy [96], necrotizing enterocolitis
[97] and extra-intestinal disorders such as neu-
ropsychiatric diseases [98, 99]. Recent case
reports suggest that FMT may be effective in gut
recolonization in patients with multi-drug
resistant oganisms like ESBLs [100, 101], CPE
[102, 103], and VRE [104] which currently have
few treatment options.
CONCLUSION
FMT is highly efficacious for patients with
multiply recurrent CDI and shows promise for a
variety of other indications. Although a number
of controlled trials have been reported, these
tend to be small and at risk of bias. Studies are
also hampered by the inherent lack of stan-
dardization involved in administering a highly
variable product. Furthermore, there are
Table 2 continued
Provider A Provider B
Clinical outcomes Primary cure rate of 94% (34/36 patients) Primary cure rate of 96% (25/26 patients)
Adverse events: diarrhea, abdominal discomfort/
cramping, bloating, ﬂatulence. Two deaths—not
related to FMT
Adverse events: diarrhea, abdominal
discomfort/cramping, bloating, ﬂatulence.
One death—aspiration pneumonia, likely
related to FMT
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significant technical, logistical, regulatory and
safety issues with the provision of FMT to
patients, both as a clinical service and in the
context of clinical research. Several of these
factors are perceived to be a major barrier which
needs to be overcome to allow more widespread
access to FMT for appropriate patient groups.
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